Lv21
170 积分 2024-10-09 加入
Evaluating the Optimal Time Between Diagnosis and Surgical Intervention for Early-Stage Lung Cancer
1个月前
已完结
Comparison of the somatic mutations between circulating tumor DNA and tissue DNA in Chinese patients with non-small cell lung cancer
1个月前
已完结
[Long-term Survival in Hospitalized Patients with Lung Cancer among Peasants
in the Coal-producing Area in Eastern Yunnan, China]
1个月前
已关闭
Phase I/II multicenter, randomized, open-label trial of the c-Met inhibitor MSC2156119J and gefitinib versus chemotherapy as second-line treatment in patients with MET-positive (MET+), locally advanced, or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor mutation (EGFRm+) and progression on gefitinib
1个月前
已关闭
Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China
1个月前
已完结
EP1.08-05 Local Non-Salvage Radiotherapy for Synchronous Oligometastatic NSCLC: A Multicenter, Randomized, Controlled, Phase 2 Study
1个月前
已完结
Randomized controlled trial of neoadjuvant chemotherapy with cisplatin and vinorelbine in patients with stage IIIA non‐small cell lung cancer in China
1个月前
已完结
SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer
1个月前
已关闭
EP1.08-05 Local Non-Salvage Radiotherapy for Synchronous Oligometastatic NSCLC: A Multicenter, Randomized, Controlled, Phase 2 Study
1个月前
已完结
Safety and efficacy of programmed cell death‐1 antibody SHR‐1210 combined with concurrent chemoradiotherapy to treat locally advanced esophageal squamous cell carcinoma: a study protocol for an exploratory single‐arm phase Ib trial
1个月前
已完结
皖公网安备34019202002308
